Review
Open access
Sep 2026
Melatonin supplementation in multiple sclerosis: a systematic review of clinical, imaging, biomarker, and safety outcomes
Current evidence does not support a disease-modifying effect of melatonin in MS, and any symptomatic or biomarker benefits need confirmation in larger, well-designed trials, and high-dose melatonin may carry meaningful hepatic risk.
Yehia Nabil, A. Ghazou, Sara Abodabesh et al.
· Frontiers in Neurology · 0 citations